3
Announcements
Trials
Browse
Landscape
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
83
Metastatic Castration Resistant Prostate Cancer
9
Breast Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Prostate Cancer Metastatic
4
Castration-resistant Prostate Cancer
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Triple Negative Breast Neoplasms
2
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Seizures
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Prostate Carcinoma Metastatic to the Bone
1
Primary Dysautonomias
1
Primary Breast Cancer ER+ve
1
Pharmacokinetics of MDV3100
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-metastatic Prostate Cancer
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Interventions
enzalutamide
2
darolutamide
2
apalutamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Non-metastatic Castration-resistant Prostate Cancer
×
enzalutamide
×
Clear all
NCT06013475
2025-06-12
DEAR-EXT
Bayer
Completed
1,375 enrolled
NCT05362149
2024-03-20
DEAR
Bayer
Completed
870 enrolled